The Phase 1 trial in 80 healthy volunteers demonstrated safety and tolerability across four dose levels with no serious adverse events
"Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs"
Early assessment and treatment can play an important part in protecting nerve function and maintaining comfort and mobility in the years ahead.
The challenge is that awareness has grown much faster than the evidence, so its become difficult for people to separate genuine science from clever marketing. For people frustrated by persistent tendon pain or recurring injuries, that marketing can be particularly persuasive
Its 0.9% benzyl alcohol content actively inhibits bacterial growth, making it suitable for multiple doses over time
Variation in Recovery Time: Everyones recovery timeline is different